|  |  |
| --- | --- |
| May 17, 2018  **Contact:**  **Regina Bárbara**  Comunicação Corporativa  Phone +55 11 3146-4170  [regina.barbara@evonik.com](mailto:regina.barbara@evonik.com) |  |
|  |  |

**Evonik Brasil Ltda.**

Rua Arq. Olavo Redig de Campos, 105

Torre A – 04711-904 - São Paulo – SP Brasil

[www.evonik.com.br](http://www.evonik.com.br)

facebook.com/Evonik

youtube.com/EvonikIndustries

linkedin.com/company/Evonik

twitter.com/Evonik

Evonik will showcase its solutions to the pharma industry at the FCE Pharma trade show

Evonik, one of the world leaders in specialty chemicals, will feature its solutions to the pharma segment at this year’s edition of the FCE Pharma – Internacional Exhibition of Technology for the Pharmaceutical Industry. The trade show will take place between May 22-24 at the São Paulo Expo in São Paulo.

The company will showcase its full product and services platform, which includes active ingredients, pioneering excipients for drug delivery, formulation services for oral and parenteral pharmaceuticals, and innovative excipients for food supplements.

“The event is an important opportunity for us to make contact with buyers of the pharmaceutical industry, broaden our relationship with our clients and strengthen our commitment to the advancement of the pharma sector through efficient and innovative solutions,” says Luis Roberto Cardoso, business director Health Care business line at Evonik.

**Evonik’s highlights at the FCE Pharma:**

**EUDRAGIT® polymers:** These excipients have beenpresent in the pharma industry for more than 60 years. Available as aqueous suspensions, granules and powders, they are distinguished for their versatility in providing immediate release or enabling pH- or time-dependent release of active ingredients.

**PlasACRYL™:** Systems developed to speed up and simplify the preparation of EUDRAGIT® suspensions for the application of gastro-resistant coatings.

**Services and technology platform:** When it comes to developing generic drug formulations or incremental innovations, Evonik has a global technical support network and well-equipped laboratories to develop and optimize formulations to meet challenges such as solubility enhancement, taste masking, and drug release modulation among others.

The following Evonik partners will participated in the show: **Meggle,** a pioneer in the development of innovative lactose-based excipients and **SRL Pharma**, a company specializing in anti-acid and digestive pharmaceutical actives.

Focus will also be placed on **amino acids, amino acid** **derivatives** and **peptides** for application in drug formulations, cell culture, food supplements, and parenteral and enteral nutrition.

The **AEROSIL®** e **AEROPERL®** brands – essential excipients used as drug glidants and carriers – will also be part of the solutions presented by Evonik at the trade show.

**Service:**

**FCE Pharma  
Date: May 22-24, 2018**

**Time: 1:00 p.m. – 8:00 p.m.**

**Place: São Paulo Expo - Rodovia dos Imigrantes, km 1.5 – Água Funda – São Paulo (SP)**

**Evonik’s booth:** Corridor I, no. 55.

**Company information**

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

**About Nutrition & Care**

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around

€4.5 billion in 2017.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.